The Company also confirms that it is pursuing licensing discussions in other therapeutic areas
The protective framework of the safeguard proceedings enables Mauna Kea Technologies to intensify discussions on financing options with long-term investors
Paris and Boston, April 01, 2025 – 8:50 a.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces entering into exclusive negotiations for a licensing agreement for its Cellvizio technology in an important therapeutic area with a major industry player.
As part of its strategic process launched a few months ago, the Company is also pursuing several licensing discussions covering other therapeutic areas, reflecting a growing interest in the Cellvizio technology across multiple medical specialties.
In parallel, and following the opening of the safeguard procedure announced on March 31, 2025, the Company intends to intensify its discussions regarding financing options with long-term investors in order to consolidate its financial position and support its future growth.
“This exclusive negotiation agreement is a concrete example of the implementation of our strategy to monetize technological assets, and demonstrates the growing attractiveness of our Cellvizio platform to major players in the industry,” said Sacha Loiseau, Chairman and CEO of Mauna Kea Technologies. “The safeguard proceedings now provide us with a structured framework to accelerate this strategy and enter into long-term discussions with industry and financial partners.”
